Virtus ETF Advisers’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-19,523
| Closed | -$340K | – | 780 |
|
|
2024
Q4 | $340K | Sell |
19,523
-25,967
| -57% | -$459K | 0.14% | 217 |
|
|
2024
Q3 | $636K | Hold |
45,490
| – | – | 0.3% | 172 |
|
|
2024
Q2 | $374K | Buy |
45,490
+1,340
| +3% | +$9.03K | 0.18% | 187 |
|
|
2024
Q1 | $340K | Buy |
44,150
+6,352
| +17% | +$53.6K | 0.18% | 216 |
|
|
2023
Q4 | $340K | Buy |
37,798
+19,817
| +110% | +$144K | 0.22% | 196 |
|
|
2023
Q3 | $161K | Sell |
17,981
-2,328
| -11% | -$32.8K | 0.1% | 308 |
|
|
2023
Q2 | $312K | Buy |
20,309
+3,635
| +22% | +$66.1K | 0.18% | 195 |
|
|
2023
Q1 | $375K | Buy |
16,674
+293
| +2% | +$6.23K | 0.21% | 152 |
|
|
2022
Q4 | $344K | Buy |
16,381
+6,362
| +63% | +$135K | 0.18% | 220 |
|
|
2022
Q3 | $247K | Buy |
10,019
+144
| +1% | +$3.72K | 0.1% | 291 |
|
|
2022
Q2 | $239K | Sell |
9,875
-4,241
| -30% | -$107K | 0.09% | 307 |
|
|
2022
Q1 | $364K | Hold |
14,116
| – | – | 0.16% | 158 |
|
|
2021
Q4 | $438K | Sell |
14,116
-15,427
| -52% | -$434K | 0.17% | 128 |
|
|
2021
Q3 | $716K | Sell |
29,543
-2,711
| -8% | -$49.8K | 0.32% | 100 |
|
|
2021
Q2 | $471K | Buy |
32,254
+8,347
| +35% | +$165K | 0.19% | 168 |
|
|
2021
Q1 | $597K | Buy |
+23,907
| New | +$661K | 0.25% | 123 |
|
|
2020
Q4 | – | Sell |
-38,150
| Closed | -$704K | – | 361 |
|
|
2020
Q3 | $704K | Buy |
38,150
+3,213
| +9% | +$62.4K | 0.37% | 104 |
|
|
2020
Q2 | $713K | Sell |
34,937
-6,123
| -15% | -$97.5K | 0.34% | 95 |
|
|
2020
Q1 | $599K | Sell |
41,060
-3,465
| -8% | -$52.1K | 0.25% | 152 |
|
|
2019
Q4 | $632K | Buy |
44,525
+8,428
| +23% | +$108K | 0.1% | 176 |
|
|
2019
Q3 | $418K | Sell |
36,097
-6,064
| -14% | -$100K | 0.08% | 187 |
|
|
2019
Q2 | $847K | Buy |
+42,161
| New | +$832K | 0.18% | 171 |
|
|
2019
Q1 | – | Sell |
-24,796
| Closed | -$561K | – | 263 |
|
|
2018
Q4 | $561K | Sell |
24,796
-3,271
| -12% | -$81.4K | 0.1% | 64 |
|
|
2018
Q3 | $806K | Buy |
28,067
+1,891
| +7% | +$54.1K | 0.08% | 66 |
|
|
2018
Q2 | $714K | Sell |
26,176
-15,627
| -37% | -$416K | 0.63% | 95 |
|
|
2018
Q1 | $935K | Sell |
41,803
-2,494
| -6% | -$59.4K | 0.81% | 52 |
|
|
2017
Q4 | $933K | Sell |
44,297
-12,356
| -22% | -$282K | 1.17% | 39 |
|
|
2017
Q3 | $1.41M | Hold |
56,653
| – | – | 0.19% | 39 |
|
|
2017
Q2 | $1.1M | Buy |
56,653
+5,036
| +10% | +$91.3K | 0.16% | 50 |
|
|
2017
Q1 | $953K | Buy |
51,617
+4,963
| +11% | +$97.1K | 0.17% | 72 |
|
|
2016
Q4 | $883K | Buy |
46,654
+9,061
| +24% | +$185K | 0.26% | 74 |
|
|
2016
Q3 | $841K | Buy |
37,593
+4,736
| +14% | +$90.2K | 0.41% | 40 |
|
|
2016
Q2 | $585K | Buy |
32,857
+4,223
| +15% | +$68.4K | 0.43% | 29 |
|
|
2016
Q1 | $391K | Hold |
28,634
| – | – | 0.54% | 51 |
|
|
2015
Q4 | $552K | Buy |
+28,634
| New | +$572K | 1.52% | 27 |
|
Other funds holding TVTX
AC
RSCM
DCM
Virtus ETF Advisers's TVTX Position: Q1 2025 in Review
Virtus ETF Advisers sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 19,523 shares — an estimated $340K sold.
Virtus ETF Advisers first reported a position in TVTX in Q4 2015 and held it in 35 quarters. The position peaked at $1.41M in Q3 2017. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.
- Virtus ETF Advisers reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 19,523 Travere Therapeutics shares in Q1 2025, an estimated $340K.
- Virtus ETF Advisers first reported a position in Travere Therapeutics in Q4 2015 and held it in 35 quarters.
- Virtus ETF Advisers's Travere Therapeutics position peaked at $1.41M in Q3 2017.
- 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.